Structure

InChI Key AUODDLQVRAJAJM-XJQDNNTCSA-N
Smile CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1.Cl
InChI
InChI=1S/C18H33ClN2O5S.ClH/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4;/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25);1H/t9-,10+,11-,12+,13-,14+,15+,16+,18+;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C18H34Cl2N2O5S
Molecular Weight 461.45
AlogP 0.39
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 7.0
Polar Surface Area 102.26
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 27.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial 70S ribosome inhibitor PubMed DailyMed Wikipedia Wikipedia

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Osteomyelitis 4 D010019 ClinicalTrials
Acne Vulgaris 4 D000152 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Immune system disorders
23.99
Skin and subcutaneous tissue disorders
12.82
Gastrointestinal disorders
12.63
General disorders and administration site conditions
10.11
Respiratory, thoracic and mediastinal disorders
4.49
Infections and infestations
4.15
Injury, poisoning and procedural complications
3.89
Nervous system disorders
3.83
Vascular disorders
3.3
Cardiac disorders
3.12
Psychiatric disorders
2.41
Musculoskeletal and connective tissue disorders
2.4
Blood and lymphatic system disorders
2.32
Investigations
2.29

Cross References

Resources Reference
ChEMBL CHEMBL1200588
EPA CompTox DTXSID4045428
FDA SRS T20OQ1YN1W
PubChem 16051951
SureChEMBL SCHEMBL3153